FRIDAY, NOVEMBER 20, 2026 Tech news, minus the noise.
N News Cast
LATEST
Startups

Isomorphic Labs Just Raised $5 Billion, the Biggest Bet Yet on AI-Designed Drugs

Alphabet's AI drug discovery company closed a $5 billion Series C led by Greenoaks and Sequoia, a round that treats AI-designed medicines as a near-term business, not a lab experiment.

Isomorphic Labs Just Raised $5 Billion, the Biggest Bet Yet on AI-Designed Drugs
Source: Unsplash (free license)

Five billion dollars for drugs designed by AI

Isomorphic Labs raised $5 billion in a Series C announced November 17, one of the largest private biotech rounds ever. Greenoaks and Sequoia Capital led the round, and the Isomorphic Labs funding total now dwarfs every other biotech AI round this year. The company is Alphabet's AI drug discovery arm, built on the same DeepMind protein-folding work that won a Nobel Prize, and it is now funded like a company that expects to put AI-designed medicines into human trials at scale.

The size is the point. A typical biotech Series C is measured in the tens or low hundreds of millions. Five billion says the investors are not funding a research project. They are funding the expensive middle of drug development: the clinical trials, the manufacturing, and the long grind of proving that molecules a model dreamed up actually work in people.

Why now, and why this much

The timing follows a year in which AI drug discovery stopped being a pitch and started producing candidates. Boltz raised $110 million earlier this month to sell drug discovery by the token, and Marrow Therapeutics launched with $173 million to deliver gene medicine into bone marrow. Isomorphic sits a level above both: it has Alphabet's compute, DeepMind's models, and now a war chest that rivals the R&D budget of a mid-sized pharma company.

The bet has two halves. The first is that AI can design better drug candidates faster than traditional screening, which is a claim the field has been making for a decade and is only now starting to prove with real clinical data. The second is that owning the drug, not just selling the software, is where the money is. Isomorphic is not positioning itself as a tools vendor. It wants to be a drug company that happens to be built on AI.

What five billion dollars actually buys

Drug development is one of the few industries where five billion dollars is a plausible budget rather than a headline number. A single Phase 3 trial can cost hundreds of millions, and most candidates fail before they get there. Isomorphic's money buys a portfolio approach: enough programs running in parallel that a few failures do not sink the company, and enough manufacturing capacity to make its own molecules instead of renting someone else's.

It also buys time, which is the scarcest resource in biotech. A startup with eighteen months of runway makes different decisions from a company with five years of it. It can run the longer, more careful trials. It can wait for the right partnership instead of taking the first one. And it can keep its research team intact through the inevitable stretches when nothing works, which is when most biotech startups lose their best people.

The comparison that matters is not with other startups but with pharma itself. The largest drug companies spend ten to twenty billion dollars a year on research. Isomorphic's round is a quarter of that, raised in one go, for a company that did not exist a decade ago. That is either the smartest money in biotech or the most expensive lesson in it, and the clinic will decide which.

What could go wrong

The honest risk is the same one that has sunk every AI drug discovery hype cycle: biology does not care about your model. Most drug candidates fail in trials for reasons no amount of compute can predict in advance, and a $5 billion round raises the stakes on every single program. If the first wave of Isomorphic candidates stalls in Phase 2, the story flips from visionary to cautionary very fast.

There is also the question of what Alphabet does with a drug company inside a tech conglomerate. Drug development runs on ten-year timelines and regulatory patience, which is not the metabolism of a company used to shipping software. Isomorphic has operated at arm's length so far, and the new money gives it room to stay that way, but the tension is real.

The bottom line

Five billion dollars is not a vote of confidence in AI drug discovery in general. It is a specific bet that Isomorphic Labs, with DeepMind's models and Alphabet's backing, is the team that turns the idea into approved medicines. The rest of the field will be watching the clinic, not the press release. That is where this round gets judged, and it will take years, not quarters.

AS
News Cast Editorial Team

We cover AI, gadgets, startups and security — original reporting and explainers, written by humans, for humans. Got a tip? Reach us via the contact page.